(firstQuint)Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia.

 Other objectives of this study include: 1.

 Assess the safety of treatment with vosaroxin, including the 30 and 60 day all-cause mortality 2.

 Assess leukemia free survival (LFS), event-free survival (EFS), overall survival (OS), and duration of remission (DR).

 3.

 Characterize the pharmacokinetic (PK) profile of vosaroxin in this patient population.

 4.

 Evaluate potential stratification biomarkers by evaluating DNA-damage and apoptotic pathways in bone marrow samples before and after treatment with vosaroxin.

 Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia@highlight

This study will evaluate the overall remission rate of treatment with vosaroxin (formerly voreloxin) Injection in patients at least 60 years of age with previously untreated AML